Acne VulgarisNCT07421804
Evaluation of Topical Dutasteride as a Potential New Therapy for Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel)
A study testing topical dutasteride in people with Acne Vulgaris, run by Assiut University.
Trial summary
Acne vulgaris (AV) is one of the most prevalent dermatological conditions worldwide, affecting approximately 85% of adolescents and young adults between the ages of 12 and 24 years .While acne is often self-limiting, it can have profound psychosocial implications as individuals with acne are more likely to experience… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acne Vulgaris
- What is being tested?
- topical dutasteride
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- Apr 2026to Apr 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with facial acne vulgaris older than 18 years.
Who cannot join
- · Unrealistic expectations.
- Unable to follow up.
- Severe and nodulocystic AV.
- Patients on topical treatment for AV (4 weeks before enrollment) and on systemic treatment for AV (3 months before enrollment).
- Patients on any systemic medication 3 months before enrollment.
- Suspicion of malignancy, including prostate cancer
Show all 10Show fewer
- History of infertility or difficulty in fathering children.
- Pregnancy \& lactation.
- Planning to become pregnant during study period or 6 months after ending treatment
- Patients with any concomitant dermatologic or systemic illness.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Clinical and Microbiological Evaluation of Topical Dutasteride as a Potential New Therapy of Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel)
Acne vulgaris (AV) is one of the most prevalent dermatological conditions worldwide, affecting approximately 85% of adolescents and young adults between the ages of 12 and 24 years .While acne is often self-limiting, it can have profound psychosocial implications as individuals with acne are more likely to experience emotional distress, lower self-esteem and anxiety disorders .
Acne Vulgaris is a chronic inflammatory skin condition affecting the pilosebaceous units that leads to the development of different skin lesions such as comedones, papules, pustules, nodules and cystic lesions .
Read the detailed description
The pathogenesis of AV involves the interaction of several host factors, including the stimulation of sebaceous glands by circulating androgens, follicular occlusion, dysbiosis of the pilosebaceous unit, and cellular immune/inflammatory responses .
Despite the availability of a wide range of treatment modalities, acne management remains challenging due to factors such as antibiotic resistance, patient adherence issues, and the varying response to treatments based on individual skin types . However, recent advances in understanding the pathogenesis of acne and developing novel therapeutic modalities have reshaped the landscape of its management .
Topical treatments remain the cornerstone of initial acne therapy and are favored over systemic options due to their lower risk of adverse effects and suitability for prolonged use. However, increasing concerns over antibiotic resistance and suboptimal outcomes have led to the exploration of alternative topical therapies .
The American Academy of Dermatology guidelines recommend a multimodal approach to therapy incorporating agents with multiple mechanisms of action to address the multifactorial pathogenesis of acne .Thus, combining treatments in an easy-to-use, fixed-dose formulation can improve treatment adherence by reducing complex drug regimens hence improve efficacy .
Adapalene is a third-generation retinoid that modulates cellular keratinization, differentiation, and proliferation . Furthermore, it is one of the most tolerable retinoids that retains its stability in the presence of Benzoyl peroxide (BPO).
Benzoyl peroxide is an antibacterial agent with mild comedolytic activity, keratolytic effects, and good efficacy and tolerability . It is unaffected by Cutibacterium acnes (C. acnes) resistance and has been used in combination with topical and oral antibiotics because of its ability to reduce resistant C. acnes populations .
Moreover, topical and oral antibiotics reduce C. acnes colonization and proliferation . Clindamycin is a widely researched and commonly prescribed antibiotic with anti-inflammatory effects that has been used for acne treatment for over 30 years . Adding clindamycin to BPO not only increases antibiotic activity , but also lessens irritation .
Altogether, the combination of these three acne treatments targets three of the four acne pathogenic pathways and may reduce the antibiotic resistance and adverse cutaneous effects observed with .Thus, CabtreoTM (1.2% clindamycin phosphate, 0.15% adapalene, and 3.1% benzoyl peroxide) topical gel was approved by the US Food and Drug Administration (FDA) in October 2023 for the treatment of moderate to severe acne vulgaris in patients aged ≥12 years .
The pathophysiology of acne is profoundly influenced by hormonal factors, particularly those that alter sebaceous gland function. Androgen hormones play a key role in acne development, with acne prevalence reaching up to 96.0% during adolescence because of changes in androgen levels during puberty . They drive acne development by altering the pilosebaceous unit, resulting in increased sebum production, keratinocyte proliferation, and inflammation .
Sebum secretion by the sebaceous glands is accelerated by the conversion of testosterone to 5α dihydrotestosterone (DHT) by type I 5α-reductase (5AR), which is strongly expressed in the sebaceous glands. Therefore, it has been proposed that type I 5AR inhibitors have the potential to improve AV .
Dutasteride inhibits both type I and type II 5α-reductase enzymes. It is approximately 100 times and 3 times more potent than finasteride to inhibit the type I and II 5α-reductase isoenzymes, respectively. Moreover, Dutasteride can also decrease serum DHT by >90%, being more effective than finasteride at reducing DHT levels .
Oral dutasteride is FDA approved for benign prostatic hyperplasia in men and is used off-label for androgenetic alopecia in both men and women .The oral formulation of dutasteride is associated with fewer side effects than finasteride but there is still elevated incidence of side effects such as sexual dysfunction ,decreased libido ,erectile dysfunction and depression .However, the topical formulation would have negligible systemic absorption, resulting in minimal systemic side effects and better drug availability at the site of action thereby offering better efficacy without any safety concerns .
Dutasteride topical solution has been previously used for treating male baldness with different concentrations. The 0.05% concentration demonstrated better efficacy than finasteride (1 mg/day). Moreover, topical dutasteride was well-tolerated, with minimal dermal irritation and no significant adverse events or withdrawals, thereby confirming its favorable safety profile.
The skin microbiome plays a role in maintaining skin health by balancing homeostatic relationships. Recent studies of AV have highlighted the role of the skin microbiome, shifting focus from individual pathogens to microbial community dynamics .
While the proliferation of C. acnes has been associated with acne, it is the diversity and specific phylotypes of C. acnes that are more directly implicated in acne development . Different strains of C. acnes can induce varying immune responses. Acne-associated strains trigger pro-inflammatory cytokines like interferon (IFN)-γ and interleukin (IL)-17, whereas health-associated strains promote the production of the anti-inflammatory IL-10 .
Cutibacterium acnes plays a pivotal role in acne pathogenesis by interacting with innate immunity through the release of extracellular enzymes and reactive oxygen species and the activation of Toll like receptors, alongside influencing sebum production, keratin, filaggrin, and insulin growth factor-1 levels. This leads to inflammation and hyperkeratosis, which maintains inflammation through acquired cell-mediated responses via T- helper 1 cells .
Bacterial biofilms are heterogeneous structures consisting of aggregates of bacterial populations embedded in a matrix that constitutes a reservoir of bacteria. The pathogenic role of biofilms is now well established in the development and exacerbation of chronic inflammatory skin diseases such as acne. The intricate composition of the biofilm protects bacteria from antibiotics and the immune system's activity. Thus, it is challenging to eradicate a bacterial biofilm once set .
Current research about acne treatment explores various facets, including sebaceous gland activity, inflammation, microbial flora and biofilm, and even systemic influences like diet, unveiling promising candidates, each targeting different aspects of acne's multifactorial nature .
- Conditions
- Acne Vulgaris
- Being tested
- topical dutasteride
- Medical subject headings
- Acne Vulgaris
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
topical dutasterideDrug
Also called Dutasteride, Triple fixed combination
- Group I will be treated by topical Dutasteride 0.05% gel versus placebo (Petrolatum) (split face).
- Group II will be treated by topical Dutasteride 0.05% gel versus topical triple fixed-dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% gel (split face).
| Study group | Role | What they receive |
|---|---|---|
| Topical Dutasteride 0.05% gel versus placebo (Petrolatum) (split face). | Experimental | Not described Receives: Drug: topical dutasteride |
| Topical Dutasteride 0.05% gel versus topical triple fixed-dose combination | Experimental | Not described Receives: Drug: topical dutasteride |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluate and compare the therapeutic efficacy (clinical, microbiological & psychological) of topical Dutasteride 0.05% versus topical fixed-dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% gel in patients with facial AV
- Total lesions count (TLC) (inflammatory lesions and noninflammatory lesions)
Measured: 16 weeks
Evaluate and compare the therapeutic efficacy (clinical, microbiological & psychological) of topical Dutasteride 0.05% versus topical fixed-dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% gel in patients with facial AV
- The investigator's global assessment (IGA) of acne severity grade modified to assess the half-face acne severity ; Treatment success will be defined as an Investigator's Global Assessment score of 0 (clear) or 1 (almost clear), and a 2-grade or greater improvement from baseline at week 12.
Measured: 12 weeks
Secondary outcomes (2)
Addressing the safety profile of the two topical therapeutics
By recording side effects by daily diary specifying side effect (whether systemic or topical ,type,site and onset )
Measured: 12 weeks
Psychological effect of AV and its relation to therapeutic outcomes
Cardiff Acne Disability Index (CADI) will be assessed at first visit and at end of 12 week-study period
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Feb 2026
- Study startApr 2026 (estimated)
- Primary completionApr 2027 (estimated)
- Study completionApr 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (16)Papers the sponsor has linked to this study.
- Other trials for Acne VulgarisStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ola Ahmed Elminshawy, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07421804
- Sponsor's protocol ID
- Topical dutasteride in AV
- Status last verified
- Feb 2026
- First submitted
- 8 Feb 2026
- Last updated
- 19 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Voutilainen A, Pitkaaho T, Kvist T, Vehvilainen-Julkunen K. How to ask about patient satisfaction? The visual analogue scale is less vulnerable to confounding factors and ceiling effect than a symmetric Likert scale. J Adv Nurs. 2016 Apr;72(4):946-57. doi: 10.1111/jan.12875. Epub 2015 Dec 22.
PubMed 26689434El-Husseiny R, Elframawy S, Abdallah M. Comparative study between fractional carbon dioxide laser vs intralesional steroid injection in treatment of alopecia areata. Dermatol Ther. 2020 Jul;33(4):e13742. doi: 10.1111/dth.13742. Epub 2020 Jul 9.
PubMed 32478930Boonpethkaew S, Ratanapokasatit Y, Chirasuthat S, Wattanakrai P. Efficacy and safety of the 589/1319 nm solid-state dual-wavelength laser combined with topical benzoyl peroxide for inflammatory acne vulgaris: a split-face randomized controlled trial. Arch Dermatol Res. 2025 Mar 26;317(1):635. doi: 10.1007/s00403-025-04146-6.
PubMed 40140055Charakida A, Charakida M, Chu AC. Double-blind, randomized, placebo-controlled study of a lotion containing triethyl citrate and ethyl linoleate in the treatment of acne vulgaris. Br J Dermatol. 2007 Sep;157(3):569-74. doi: 10.1111/j.1365-2133.2007.08083.x. Epub 2007 Jul 16.
PubMed 17635508Elradi M, Hamed DE, Eltwansy MS, Hosny D. The Impact of Acne on Quality of Life: A Cross-Sectional Study from Egypt. Skin Appendage Disord. 2025 Jun;11(3):255-261. doi: 10.1159/000543051. Epub 2024 Dec 10.
PubMed 40475110Kim KY, Song SY, Jung YJ, Jue MS, Hong JY, Kim BJ, Ko JY. A Randomized, Split-Face, Comparative Study of a Combined Needle Radiofrequency/Intense Pulsed Light Device in Moderate-to-Severe Acne Patients. Ann Dermatol. 2024 Oct;36(5):266-274. doi: 10.5021/ad.23.083.
PubMed 39343753Kim HJ, Kim YH. Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies. Int J Mol Sci. 2024 May 13;25(10):5302. doi: 10.3390/ijms25105302.
PubMed 38791344Beylot C, Auffret N, Poli F, Claudel JP, Leccia MT, Del Giudice P, Dreno B. Propionibacterium acnes: an update on its role in the pathogenesis of acne. J Eur Acad Dermatol Venereol. 2014 Mar;28(3):271-8. doi: 10.1111/jdv.12224. Epub 2013 Aug 1.
PubMed 23905540Almudimeegh A, AlMutairi H, AlTassan F, AlQuraishi Y, Nagshabandi KN. Comparison between dutasteride and finasteride in hair regrowth and reversal of miniaturization in male and female androgenetic alopecia: a systematic review. Dermatol Reports. 2024 Apr 12;16(4):9909. doi: 10.4081/dr.2024.9909. eCollection 2024 Nov 21.
PubMed 39749123Leyden J, Bergfeld W, Drake L, Dunlap F, Goldman MP, Gottlieb AB, Heffernan MP, Hickman JG, Hordinsky M, Jarrett M, Kang S, Lucky A, Peck G, Phillips T, Rapaport M, Roberts J, Savin R, Sawaya ME, Shalita A, Shavin J, Shaw JC, Stein L, Stewart D, Strauss J, Swinehart J, Swinyer L, Thiboutot D, Washenik K, Weinstein G, Whiting D, Pappas F, Sanchez M, Terranella L, Waldstreicher J. A systemic type I 5 alpha-reductase inhibitor is ineffective in the treatment of acne vulgaris. J Am Acad Dermatol. 2004 Mar;50(3):443-7. doi: 10.1016/j.jaad.2003.07.021.
PubMed 14988688Panuganti VK, Kumar Madala P, Ramalingayya Grandhi V, Varma Alluri C, Mohammad J, Rao Kssvv S, Reddy Dundigalla M. A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia. Cureus. 2025 Aug 3;17(8):e89309. doi: 10.7759/cureus.89309. eCollection 2025 Aug.
PubMed 40909044Del Rosso JQ, Kircik L. The cutaneous effects of androgens and androgen-mediated sebum production and their pathophysiologic and therapeutic importance in acne vulgaris. J Dermatolog Treat. 2024 Dec;35(1):2298878. doi: 10.1080/09546634.2023.2298878. Epub 2024 Jan 8.
PubMed 38192024Gupta AK, Mann A, Vincent K, Abramovits W. CABTREOTM (Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide) Topical Gel. Skinmed. 2024 Oct 22;22(5):375-378. eCollection 2024.
PubMed 39433524Stein Gold L, Baldwin H, Kircik LH, Weiss JS, Pariser DM, Callender V, Lain E, Gold M, Beer K, Draelos Z, Sadick N, Pillai R, Bhatt V, Tanghetti EA. Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug. Am J Clin Dermatol. 2022 Jan;23(1):93-104. doi: 10.1007/s40257-021-00650-3. Epub 2021 Oct 21.
PubMed 34674160Reynolds RV, Yeung H, Cheng CE, Cook-Bolden F, Desai SR, Druby KM, Freeman EE, Keri JE, Stein Gold LF, Tan JKL, Tollefson MM, Weiss JS, Wu PA, Zaenglein AL, Han JM, Barbieri JS. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024 May;90(5):1006.e1-1006.e30. doi: 10.1016/j.jaad.2023.12.017. Epub 2024 Jan 30.
PubMed 38300170
Study at a glance
From the registry record, last updated by the sponsor on 19 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical and Microbiological Evaluation of Topical Dutasteride as a Potential New Therapy of Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel)
- ClinicalTrials.gov ID
- NCT07421804
- Acronym / sponsor ID
- Topical dutasteride in AV
- Conditions
- Acne Vulgaris
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- Apr 2026 (estimated)
- Primary completion
- Apr 2027 (estimated)
- Study completion
- Apr 2028 (estimated)
- First posted
- 19 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Acne vulgaris (AV) is one of the most prevalent dermatological conditions worldwide, affecting approximately 85% of adolescents and young adults between the ages of 12 and 24 years .While acne is often self-limiting, it can have profound psychosocial implications as individuals with acne are more likely to experience emotional distress, lower self-esteem and anxiety disorders .
Acne Vulgaris is a chronic inflammatory skin condition affecting the pilosebaceous units that leads to the development of different skin lesions such as comedones, papules, pustules, nodules and cystic lesions .
Detailed description
The pathogenesis of AV involves the interaction of several host factors, including the stimulation of sebaceous glands by circulating androgens, follicular occlusion, dysbiosis of the pilosebaceous unit, and cellular immune/inflammatory responses .
Despite the availability of a wide range of treatment modalities, acne management remains challenging due to factors such as antibiotic resistance, patient adherence issues, and the varying response to treatments based on individual skin types . However, recent advances in understanding the pathogenesis of acne and developing novel therapeutic modalities have reshaped the landscape of its management .
Topical treatments remain the cornerstone of initial acne therapy and are favored over systemic options due to their lower risk of adverse effects and suitability for prolonged use. However, increasing concerns over antibiotic resistance and suboptimal outcomes have led to the exploration of alternative topical therapies .
The American Academy of Dermatology guidelines recommend a multimodal approach to therapy incorporating agents with multiple mechanisms of action to address the multifactorial pathogenesis of acne .Thus, combining treatments in an easy-to-use, fixed-dose formulation can improve treatment adherence by reducing complex drug regimens hence improve efficacy .
Adapalene is a third-generation retinoid that modulates cellular keratinization, differentiation, and proliferation . Furthermore, it is one of the most tolerable retinoids that retains its stability in the presence of Benzoyl peroxide (BPO).
Benzoyl peroxide is an antibacterial agent with mild comedolytic activity, keratolytic effects, and good efficacy and tolerability . It is unaffected by Cutibacterium acnes (C. acnes) resistance and has been used in combination with topical and oral antibiotics because of its ability to reduce resistant C. acnes populations .
Moreover, topical and oral antibiotics reduce C. acnes colonization and proliferation . Clindamycin is a widely researched and commonly prescribed antibiotic with anti-inflammatory effects that has been used for acne treatment for over 30 years . Adding clindamycin to BPO not only increases antibiotic activity , but also lessens irritation .
Altogether, the combination of these three acne treatments targets three of the four acne pathogenic pathways and may reduce the antibiotic resistance and adverse cutaneous effects observed with .Thus, CabtreoTM (1.2% clindamycin phosphate, 0.15% adapalene, and 3.1% benzoyl peroxide) topical gel was approved by the US Food and Drug Administration (FDA) in October 2023 for the treatment of moderate to severe acne vulgaris in patients aged ≥12 years .
The pathophysiology of acne is profoundly influenced by hormonal factors, particularly those that alter sebaceous gland function. Androgen hormones play a key role in acne development, with acne prevalence reaching up to 96.0% during adolescence because of changes in androgen levels during puberty . They drive acne development by altering the pilosebaceous unit, resulting in increased sebum production, keratinocyte proliferation, and inflammation .
Sebum secretion by the sebaceous glands is accelerated by the conversion of testosterone to 5α dihydrotestosterone (DHT) by type I 5α-reductase (5AR), which is strongly expressed in the sebaceous glands. Therefore, it has been proposed that type I 5AR inhibitors have the potential to improve AV .
Dutasteride inhibits both type I and type II 5α-reductase enzymes. It is approximately 100 times and 3 times more potent than finasteride to inhibit the type I and II 5α-reductase isoenzymes, respectively. Moreover, Dutasteride can also decrease serum DHT by >90%, being more effective than finasteride at reducing DHT levels .
Oral dutasteride is FDA approved for benign prostatic hyperplasia in men and is used off-label for androgenetic alopecia in both men and women .The oral formulation of dutasteride is associated with fewer side effects than finasteride but there is still elevated incidence of side effects such as sexual dysfunction ,decreased libido ,erectile dysfunction and depression .However, the topical formulation would have negligible systemic absorption, resulting in minimal systemic side effects and better drug availability at the site of action thereby offering better efficacy without any safety concerns .
Dutasteride topical solution has been previously used for treating male baldness with different concentrations. The 0.05% concentration demonstrated better efficacy than finasteride (1 mg/day). Moreover, topical dutasteride was well-tolerated, with minimal dermal irritation and no significant adverse events or withdrawals, thereby confirming its favorable safety profile.
The skin microbiome plays a role in maintaining skin health by balancing homeostatic relationships. Recent studies of AV have highlighted the role of the skin microbiome, shifting focus from individual pathogens to microbial community dynamics .
While the proliferation of C. acnes has been associated with acne, it is the diversity and specific phylotypes of C. acnes that are more directly implicated in acne development . Different strains of C. acnes can induce varying immune responses. Acne-associated strains trigger pro-inflammatory cytokines like interferon (IFN)-γ and interleukin (IL)-17, whereas health-associated strains promote the production of the anti-inflammatory IL-10 .
Cutibacterium acnes plays a pivotal role in acne pathogenesis by interacting with innate immunity through the release of extracellular enzymes and reactive oxygen species and the activation of Toll like receptors, alongside influencing sebum production, keratin, filaggrin, and insulin growth factor-1 levels. This leads to inflammation and hyperkeratosis, which maintains inflammation through acquired cell-mediated responses via T- helper 1 cells .
Bacterial biofilms are heterogeneous structures consisting of aggregates of bacterial populations embedded in a matrix that constitutes a reservoir of bacteria. The pathogenic role of biofilms is now well established in the development and exacerbation of chronic inflammatory skin diseases such as acne. The intricate composition of the biofilm protects bacteria from antibiotics and the immune system's activity. Thus, it is challenging to eradicate a bacterial biofilm once set .
Current research about acne treatment explores various facets, including sebaceous gland activity, inflammation, microbial flora and biofilm, and even systemic influences like diet, unveiling promising candidates, each targeting different aspects of acne's multifactorial nature .
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Topical Dutasteride 0.05% gel versus placebo (Petrolatum) (split face). | Experimental | Drug: topical dutasteride |
| Topical Dutasteride 0.05% gel versus topical triple fixed-dose combination | Experimental | Drug: topical dutasteride |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients with facial acne vulgaris older than 18 years.
Key exclusion criteria (10 listed)
- · Unrealistic expectations.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| topical dutasterideAlso: Dutasteride, Triple fixed combination* Group I will be treated by topical Dutasteride 0.05% gel versus placebo (Petrolatum) (split face). * Group II will be treated by topical Dutasteride 0.05% gel versus topical triple fixed-dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% gel (split face). | Drug | Topical Dutasteride 0.05% gel versus placebo (Petrolatum) (split face)., Topical Dutasteride 0.05% gel versus topical triple fixed-dose combination |
Primary outcome
Evaluate and compare the therapeutic efficacy (clinical, microbiological & psychological) of topical Dutasteride 0.05% versus topical fixed-dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% gel in patients with facial AV
Time frame: 16 weeks
o Total lesions count (TLC) (inflammatory lesions and noninflammatory lesions)
Evaluate and compare the therapeutic efficacy (clinical, microbiological & psychological) of topical Dutasteride 0.05% versus topical fixed-dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% gel in patients with facial AV
Time frame: 12 weeks
o The investigator's global assessment (IGA) of acne severity grade modified to assess the half-face acne severity ; Treatment success will be defined as an Investigator's Global Assessment score of 0 (clear) or 1 (almost clear), and a 2-grade or greater improvement from baseline at week 12.
2 secondary outcomes
Addressing the safety profile of the two topical therapeutics
Time frame: 12 weeks
Psychological effect of AV and its relation to therapeutic outcomes
Time frame: 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Feb 2026.
- Background: PubMed 26689434Voutilainen A, Pitkaaho T, Kvist T, Vehvilainen-Julkunen K. How to ask about patient satisfaction? The visual analogue scale is less vulnerable to confounding factors and ceiling effect than a symmetric Likert scale. J Adv Nurs. 2016 Apr;72(4):946-57. doi: 10.1111/jan.12875. Epub 2015 Dec 22.
- Background: PubMed 32478930El-Husseiny R, Elframawy S, Abdallah M. Comparative study between fractional carbon dioxide laser vs intralesional steroid injection in treatment of alopecia areata. Dermatol Ther. 2020 Jul;33(4):e13742. doi: 10.1111/dth.13742. Epub 2020 Jul 9.
- Background: PubMed 40140055Boonpethkaew S, Ratanapokasatit Y, Chirasuthat S, Wattanakrai P. Efficacy and safety of the 589/1319 nm solid-state dual-wavelength laser combined with topical benzoyl peroxide for inflammatory acne vulgaris: a split-face randomized controlled trial. Arch Dermatol Res. 2025 Mar 26;317(1):635. doi: 10.1007/s00403-025-04146-6.
- Background: PubMed 17635508Charakida A, Charakida M, Chu AC. Double-blind, randomized, placebo-controlled study of a lotion containing triethyl citrate and ethyl linoleate in the treatment of acne vulgaris. Br J Dermatol. 2007 Sep;157(3):569-74. doi: 10.1111/j.1365-2133.2007.08083.x. Epub 2007 Jul 16.
- Background: PubMed 40475110Elradi M, Hamed DE, Eltwansy MS, Hosny D. The Impact of Acne on Quality of Life: A Cross-Sectional Study from Egypt. Skin Appendage Disord. 2025 Jun;11(3):255-261. doi: 10.1159/000543051. Epub 2024 Dec 10.
- Background: PubMed 39343753Kim KY, Song SY, Jung YJ, Jue MS, Hong JY, Kim BJ, Ko JY. A Randomized, Split-Face, Comparative Study of a Combined Needle Radiofrequency/Intense Pulsed Light Device in Moderate-to-Severe Acne Patients. Ann Dermatol. 2024 Oct;36(5):266-274. doi: 10.5021/ad.23.083.
- Background: PubMed 38791344Kim HJ, Kim YH. Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies. Int J Mol Sci. 2024 May 13;25(10):5302. doi: 10.3390/ijms25105302.
- Background: PubMed 23905540Beylot C, Auffret N, Poli F, Claudel JP, Leccia MT, Del Giudice P, Dreno B. Propionibacterium acnes: an update on its role in the pathogenesis of acne. J Eur Acad Dermatol Venereol. 2014 Mar;28(3):271-8. doi: 10.1111/jdv.12224. Epub 2013 Aug 1.
- Background: PubMed 39749123Almudimeegh A, AlMutairi H, AlTassan F, AlQuraishi Y, Nagshabandi KN. Comparison between dutasteride and finasteride in hair regrowth and reversal of miniaturization in male and female androgenetic alopecia: a systematic review. Dermatol Reports. 2024 Apr 12;16(4):9909. doi: 10.4081/dr.2024.9909. eCollection 2024 Nov 21.
- Background: PubMed 14988688Leyden J, Bergfeld W, Drake L, Dunlap F, Goldman MP, Gottlieb AB, Heffernan MP, Hickman JG, Hordinsky M, Jarrett M, Kang S, Lucky A, Peck G, Phillips T, Rapaport M, Roberts J, Savin R, Sawaya ME, Shalita A, Shavin J, Shaw JC, Stein L, Stewart D, Strauss J, Swinehart J, Swinyer L, Thiboutot D, Washenik K, Weinstein G, Whiting D, Pappas F, Sanchez M, Terranella L, Waldstreicher J. A systemic type I 5 alpha-reductase inhibitor is ineffective in the treatment of acne vulgaris. J Am Acad Dermatol. 2004 Mar;50(3):443-7. doi: 10.1016/j.jaad.2003.07.021.
- Background: PubMed 40909044Panuganti VK, Kumar Madala P, Ramalingayya Grandhi V, Varma Alluri C, Mohammad J, Rao Kssvv S, Reddy Dundigalla M. A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia. Cureus. 2025 Aug 3;17(8):e89309. doi: 10.7759/cureus.89309. eCollection 2025 Aug.
- Background: PubMed 38192024Del Rosso JQ, Kircik L. The cutaneous effects of androgens and androgen-mediated sebum production and their pathophysiologic and therapeutic importance in acne vulgaris. J Dermatolog Treat. 2024 Dec;35(1):2298878. doi: 10.1080/09546634.2023.2298878. Epub 2024 Jan 8.
- Individual participant dataSharing planned: No
Related trials for Acne Vulgaris
Not yet recruitingPhase 3
Evaluation of the Efficacy and Safety of Fractional CO₂ Laser With and Without Intradermal Botulinum Toxin A in the Treatment of Inflammatory Facial Acne Vulgaris.
Acne, Acne Papulopustulosa
RecruitingPhase 4
Safety, Tolerability, and Clinical Effectiveness of Adapalene/Clindamycin Phosphate Gel (Klenzit®-C) in Vietnamese Patients With Mild to Moderate Acne Vulgaris
Acne
RecruitingPhase 3
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
Acne Vulgaris
RecruitingPhase 4
Comparing Nadifloxacin Plus Tretinoin Versus Clindamycin Plus Tretinoin Creams for Mild-to-Moderate Acne
Acne Vulgaris
Active, not recruiting
Clinical Study to Evaluate the Safety and Efficacy of Candela Technology
Hair Reduction, Tattoo Removal
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing topical dutasteride in people with Acne Vulgaris, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 19 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ola A Elminshawy, M.Sc. (+201112693230, ola-elminshawy@aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluate and compare the therapeutic efficacy (clinical, microbiological & psychological) of topical Dutasteride 0.05% versus topical fixed-dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% gel in patients with facial AV (time frame: 16 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07421804, which also lists 16 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Feb 2026.